文献速递前列腺癌

直接MRI与PSA引导扫描在前列腺癌筛查中的比较:主流实施的准备程度

Primary MRI versus PSA-gated scans in Prostate Cancer Screening - how ready is it for mainstream implementation?
PubMed 文献 · Prostate Cancer Prostatic Dis · 2025-11-06

该系统综述纳入17项研究,比较直接MRI筛查与PSA异常触发MRI筛查的前列腺癌检出率。直接MRI筛查对临床显著前列腺癌的检出率更高(5.93% vs 1.15%,p=0.0180),但临床不显著癌检出率无显著差异。直接比较研究中直接MRI检出优势的OR为2.32(95%CI 1.37-3.96)。

要点

  • 直接MRI筛查较PSA引导MRI显著提高临床显著前列腺癌检出率,但临床不显著癌检出亦增加。
  • 直接比较研究显示直接MRI对临床显著前列腺癌检出的OR为2.32(95%CI 1.37-3.96)。
  • 主流实施前需更多成本效果学证据,且存在验证偏倚和异质性。

核心结论

  • 直接MRI筛查对临床显著前列腺癌的检出率高于以PSA阈值3-4 ng/ml触发的PSA引导MRI筛查。
  • 直接MRI筛查也增加了临床不显著前列腺癌的检出和穿刺活检的采用。
  • 主流实施前需要更精细的成本效果学结果。

研究设计与样本

  • 系统综述,检索Pubmed、Embase、Web of Science、CENTRAL、Scopus和Google Scholar从2000年1月1日至2024年4月20日。
  • 纳入研究一般成年男性人群(未进行其他风险分层)的17项研究。
  • 提取结局包括临床显著前列腺癌(ISUP分级组≥2)和临床不显著前列腺癌(ISUP分级组1)的检出率及活检率。

主要发现

  • 纳入所有研究时,直接MRI较PSA引导MRI对全部前列腺癌检出率更高(8.49% vs 1.88%,p=0.0223)。
  • 直接MRI对临床显著前列腺癌检出率更高(5.93% vs 1.15%,p=0.0180)。
  • 两组间临床不显著前列腺癌检出率无统计学显著差异。
  • 直接比较研究中,直接MRI对全部前列腺癌检出的OR为2.77(95%CI 1.71-4.49)。
  • 直接比较研究中,直接MRI对临床显著前列腺癌检出的OR为2.32(95%CI 1.37-3.96),对临床不显著前列腺癌检出的OR为3.11(95%CI 1.08-8.97)。

临床怎么用

  • 在筛查场景中,直接MRI策略可能提高临床显著前列腺癌的检出,但需权衡临床不显著癌过度检出和活检增加的风险。
  • PSA引导MRI筛查以PSA阈值3-4 ng/ml触发时可能低估临床显著前列腺癌的检出。

局限性

  • 存在验证偏倚。
  • 研究间存在异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Abnormal PSA test results leading to MRI scans is mainstream practice in prostate cancer diagnosis. However, a similar algorithm may lead to under-detection of clinically significant prostate cancer (csPCa) in disease screening. We compare cancer detection rates (CDR) in screening with MRI prostate only ('primary' MRI) compared to MRI scans triggered by abnormal serum PSA levels ('PSA-gated' MRI). METHODS: Pubmed, Embase, Web of Science, CENTRAL, Scopus and Google Scholar were searched using key terms of "MRI", "prostate cancer", and "screening" from 01/1/2000-20/4/2024. We included studies investigating the general adult male population not otherwise risk stratified, and extracted outcomes of CDR for csPCa (ISUP Grade Group ≥ 2) and clinically insignificant prostate cancer (ciPCa) (ISUP Grade Group 1), and biopsy rate. RESULTS: 17 studies were included for final analysis. When including all studies, primary MRI had a higher CDR compared to PSA-gated MRI for all prostate cancer (8.49% vs. 1.88%, p = 0.0223) and csPCa (5.93% vs. 1.15%, p = 0.0180) detection respectively. There was no statistically significant difference in CDR for ciPCa between both groups. In studies directly comparing primary and PSA-gated MRI, primary MRI demonstrated higher odds of detection for all prostate cancer (OR 2.77, 95%CI: 1.71-4.49), csPCa (OR 2.32, 95%CI: 1.37-3.96) and ciPCa (OR 3.11, 95%CI: 1.08-8.97). Limitations include verification bias and heterogeneity between studies. CONCLUSIONS: Primary MRI screening demonstrated higher CDR for csPCa than PSA-gated MRI screening triggered at PSA thresholds of 3-4 ng/ml. There is also higher CDR of ciPCa and adoption of needle biopsies. More granular cost-effectiveness outcomes are required before mainstream implementation is possible.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Lim JH, Lo CY, Sultana R, et al. Primary MRI versus PSA-gated scans in Prostate Cancer Screening - how ready is it for mainstream implementation? Prostate Cancer Prostatic Dis. 2025. PMID: 41198919. doi:10.1038/s41391-025-01048-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。